Lupin receives tentative approval from USFDA for Canagliflozin Tablets

Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor

Evive Biotech and Acrotech Biopharma receive FDA approval of Ryzneuta

Health Minister Mandaviya delivers keynote address 2nd Voice of Global South Summit 2023

Emphasizes the need for a collective effort on bolstering resilience across economies, societies, healthcare systems, education systems and infrastructure

Dr. Reddy's rolls out drug-free non-invasive migraine management device ‘Nerivio’ in India

Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain

Alkem healthy lungs initiative to promote importance of inhalation therapy

The countrywide initiative aims to spread awareness, educate the public & ensure that no one is left behind in the fight against respiratory diseases

Teva, Royalty Pharma collaborate to further accelerate Olanzapine LAI program

Phase 3 data expected in the second half of 2024

Lupin receives USFDA tentative approval for Canagliflozin and Metformin Hydrochloride ER Tablets

This product will be manufactured at Lupin’s Pithampur facility in India

Aster DM Healthcare launches a 506-bed multi-specialty hospital in Bengaluru

Aster Whitefield will be Aster's 3 rd multi-specialty hospital in Bengaluru and overall 19th hospital in India

Indian Health Minister Dr. Mandaviya addresses 76th session of the WHO Regional Committee for South-East Asia

India is following a holistic and inclusive approach in alignment with the vison of Universal Health Coverage and the resolute commitment to ‘leave no one behind

Lilly's Retevmo phase 3 results in RET fusion-positive non-small cell lung cancer

In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)